Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 6/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745682 | 0.94 | SELP (0.43) | SELPSLC6A2SSTR1SSTR2SSTR4 | |
| SCHEMBL27055012 | 0.94 | SELP (0.42) | SELPSLC6A2SSTR1SSTR2SSTR4 | |
| SCHEMBL29827837 | 0.91 | SSTR1 (0.42) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL27054862 | 0.89 | SELP (0.37) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16772388 | 0.88 | SELP (0.39) | SELPSLC6A2 | |
| SCHEMBL16772382 | 0.88 | SELP (0.39) | SELPSLC6A2 | |
| SCHEMBL30829360 | 0.87 | SELP (0.41) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13925621 | 0.86 | SSTR1 (0.40) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL29827596 | 0.86 | SELP (0.39) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13701514 | 0.84 | BCHE (0.38) | SELPBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381206-A1 | INVARIANT NATURAL KILLER T-CELL ACTIVATORS | DECIDUOUS THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2024050020-A1 | INVARIANT NATURAL KILLER T-CELL ACTIVATORS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4301374-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | Deciduous Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117222414-A | Compounds for activating constant natural killer T-cells and methods for eliminating inflammatory senescent cells | 脱落性治疗公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022187141-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381206-A1 | INVARIANT NATURAL KILLER T-CELL ACTIVATORS | IL2, PBK, IFNG | SELP 1371/4885SLC6A2 4867/4885SSTR1 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.